Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tonix Pharmaceuticals Holding Corp. TNXP
$1.87
+$0.08 (4.47%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
111855062.00000000
-
week52high
29.94
-
week52low
1.77
-
Revenue
0
-
P/E TTM
0
-
Beta
2.18166000
-
EPS
-3.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Noble Capital Markets | Outperform | 18 апр 2022 г. | |
| Roth Capital | Buy | Neutral | 18 ноя 2019 г. |
| B. Riley FBR | Neutral | Buy | 18 ноя 2019 г. |
| Roth Capital | Buy | Neutral | 18 апр 2019 г. |
| Roth Capital | Neutral | Buy | 27 июл 2018 г. |
| Alliance Global Partners | Buy | 12 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LEDERMAN SETH | A | 24235 | 20000 | 29 июн 2022 г. |
| Taylor Carolyn E. | A | 2131500 | 2131500 | 09 мая 2022 г. |
| BAGGER RICHARD H | A | 2131500 | 2131500 | 09 мая 2022 г. |
| GRANGE DAVID L | A | 2131500 | 2131500 | 09 мая 2022 г. |
| Bell Margaret Smith | A | 2131500 | 2131500 | 09 мая 2022 г. |
| OLUKOTUN ADEOYE Y | A | 2131500 | 2131500 | 09 мая 2022 г. |
| Treco James | A | 2131500 | 2131500 | 09 мая 2022 г. |
| LEDERMAN SETH | A | 112177 | 100000 | 25 мар 2022 г. |
| LEDERMAN SETH | A | 5000000 | 5000000 | 15 февр 2022 г. |
| MORRIS JESSICA EDGAR | A | 1100000 | 1100000 | 15 февр 2022 г. |
Новостная лента
Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conference
Proactive Investors
23 мар 2023 г. в 16:41
Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp EVP of translation medicine Herbert Harris delivered an oral presentation Thursday at the Rare Disease Innovation and Partnership Summit in Philadelphia, the company announced. The presentation, titled, “TNX-2900 (Intranasal Potentiated Oxytocin) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome,” includes data showing the enhancing effects of magnesium on the activation of oxytocin receptors.
Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit
GlobeNewsWire
22 мар 2023 г. в 07:00
CHATHAM, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET.
Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodies
Proactive Investors
13 февр 2023 г. в 08:01
Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. said it has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the treatment or prophylaxis of SARS-CoV-2 infection. SARS-CoV-2 is the cause of COVID-19.
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
GlobeNewsWire
03 февр 2023 г. в 07:00
CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.
Using News to Find Penny Stocks to Buy: 3 Tips
PennyStocks
09 янв 2023 г. в 06:00
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.